{"title": "Nucleotide Analogues as Inhibitors of SARS-CoV Polymerase", "doi": "10.1101/2020.03.12.989186", "citation_id": "2020.03.12.989186v1", "date": "2020-03-14", "laguage": "en", "journal_title": "bioRxiv", "first_page": "2020.03.12.989186", "abstract": "<p>SARS-CoV-2, a member of the coronavirus family, has caused a global public health emergency. Based on our analysis of hepatitis C virus and coronavirus replication, and the molecular structures and activities of viral inhibitors, we previously reasoned that the FDA-approved heptatitis C drug EPCLUSA (Sofosbuvir/Velpatasvir) should inhibit coronaviruses, including SARS-CoV-2. Here, using model polymerase extension experiments, we demonstrate that the activated triphosphate form of Sofosbuvir is incorporated by low-fidelity polymerases and SARS-CoV RNA-dependent RNA polymerase (RdRp), and blocks further incorporation by these polymerases; the activated triphosphate form of Sofosbuvir is not incorporated by a host-like high-fidelity DNA polymerase. Using the same molecular insight, we selected two other anti-viral agents, Alovudine and AZT (an FDA approved HIV/AIDS drug) for evaluation as inhibitors of SARS-CoV RdRp. We demonstrate the ability of two HIV reverse transcriptase inhibitors, 3\u2032-fluoro-3\u2032-deoxythymidine triphosphate and 3\u2032-azido-3\u2032-deoxythymidine triphosphate (the active triphosphate forms of Alovudine and AZT), to be incorporated by SARS-CoV RdRp where they also terminate further polymerase extension. Given the 98% amino acid similarity of the SARS-CoV and SARS-CoV-2 RdRps, we expect these nucleotide analogues would also inhibit the SARS-CoV-2 polymerase. These results offer guidance to further modify these nucleotide analogues to generate more potent broad-spectrum anti-coronavirus agents.</p>", "twitter_description": "SARS-CoV-2, a member of the coronavirus family, has caused a global public health emergency.[1][1] Based on our analysis of hepatitis C virus and coronavirus replication, and the molecular structures and activities of viral inhibitors, we previously reasoned that the FDA-approved heptatitis C drug EPCLUSA (Sofosbuvir/Velpatasvir) should inhibit coronaviruses, including SARS-CoV-2.[2][2] Here, using model polymerase extension experiments, we demonstrate that the activated triphosphate form of Sofosbuvir is incorporated by low-fidelity polymerases and SARS-CoV RNA-dependent RNA polymerase (RdRp), and blocks further incorporation by these polymerases; the activated triphosphate form of Sofosbuvir is not incorporated by a host-like high-fidelity DNA polymerase. Using the same molecular insight, we selected two other anti-viral agents, Alovudine and AZT (an FDA approved HIV/AIDS drug) for evaluation as inhibitors of SARS-CoV RdRp. We demonstrate the ability of two HIV reverse transcriptase inhibitors, 3\u2019-fluoro-3\u2019-deoxythymidine triphosphate and 3\u2019-azido-3\u2019-deoxythymidine triphosphate (the active triphosphate forms of Alovudine and AZT), to be incorporated by SARS-CoV RdRp where they also terminate further polymerase extension. Given the 98% amino acid similarity of the SARS-CoV and SARS-CoV-2 RdRps, we expect these nucleotide analogues would also inhibit the SARS-CoV-2 polymerase. These results offer guidance to further modify these nucleotide analogues to generate more potent broad-spectrum anti-coronavirus agents.\n\n [1]: #ref-1\n [2]: #ref-2", "full_text_html_url": "https://www.biorxiv.org/content/10.1101/2020.03.12.989186v1.full", "public_url": "https://www.biorxiv.org/content/10.1101/2020.03.12.989186v1", "abstract_html_url": "https://www.biorxiv.org/content/10.1101/2020.03.12.989186v1.abstract", "pdf_url": "https://www.biorxiv.org/content/biorxiv/early/2020/03/14/2020.03.12.989186.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at http://creativecommons.org/licenses/by-nc-nd/4.0/", "publisher": "Cold Spring Harbor Laboratory", "pisa": "biorxiv;2020.03.12.989186v1", "access_rights": "restricted", "authors": ["Jingyue Ju", "Xiaoxu Li", "Shiv Kumar", "Steffen Jockusch", "Minchen Chien", "Chuanjuan Tao", "Irina Morozova", "Sergey Kalachikov", "Robert N. Kirchdoerfer", "James J. Russo"]}